NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

106.18 -2.67 (-2.45%)
At close: April 25 at 4:00 PM EDT
106.14 -0.04 (-0.04%)
After hours: April 25 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,754,000.00
6,754,000.00
18,875,000.00
17,736,000.00
274,000.00
Cost of Revenue
4,693,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Gross Profit
2,061,000.00
2,061,000.00
13,459,000.00
15,119,000.00
266,000.00
Operating Expense
6,300,000.00
6,300,000.00
4,039,000.00
1,823,000.00
1,029,000.00
Operating Income
-4,239,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Net Non Operating Interest Income Expense
383,000.00
383,000.00
171,000.00
18,000.00
25,000.00
Other Income Expense
-86,000.00
-86,000.00
-16,000.00
-29,000.00
-6,000.00
Pretax Income
-3,942,000.00
-3,942,000.00
9,575,000.00
13,285,000.00
-744,000.00
Tax Provision
772,000.00
772,000.00
1,213,000.00
1,083,000.00
3,000.00
Net Income Common Stockholders
-4,714,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Diluted NI Available to Com Stockholders
-4,714,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Basic EPS
-12.33
-12.33
21.26
30.31
-1.96
Diluted EPS
-12.33
-12.33
20.12
28.29
-1.96
Basic Average Shares
382,000.00
382,000.00
394,000.00
403,000.00
381,000.00
Diluted Average Shares
382,000.00
382,000.00
416,000.00
431,000.00
381,000.00
Total Operating Income as Reported
-4,239,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Total Expenses
10,993,000.00
10,993,000.00
9,455,000.00
4,440,000.00
1,037,000.00
Net Income from Continuing & Discontinued Operation
-4,714,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Normalized Income
-4,657,120.00
-4,657,120.00
8,379,460.00
12,202,000.00
-747,000.00
Interest Income
421,000.00
421,000.00
200,000.00
18,000.00
25,000.00
Interest Expense
38,000.00
38,000.00
29,000.00
18,000.00
9,886.00
Net Interest Income
383,000.00
383,000.00
171,000.00
18,000.00
25,000.00
EBIT
-3,904,000.00
-3,904,000.00
9,604,000.00
13,296,000.00
-763,000.00
EBITDA
-3,283,000.00
-3,283,000.00
9,952,000.00
13,528,000.00
-732,000.00
Reconciled Cost of Revenue
4,693,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Reconciled Depreciation
621,000.00
621,000.00
348,000.00
232,000.00
31,000.00
Net Income from Continuing Operation Net Minority Interest
-4,714,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Total Unusual Items Excluding Goodwill
-72,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Total Unusual Items
-72,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Normalized EBITDA
-3,211,000.00
-3,211,000.00
9,972,000.00
13,528,000.00
-732,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-15,120.00
-15,120.00
-2,540.00
--
--
12/31/2020 - 12/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BNTX BioNTech SE
86.71
-1.57%
 
NVAX Novavax, Inc.
3.9500
-4.82%
 
CRSP CRISPR Therapeutics AG
53.73
-3.45%
 
VKTX Viking Therapeutics, Inc.
68.86
+5.82%
 
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
 
NVO Novo Nordisk A/S
125.79
-0.29%
 
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
 
REGN Regeneron Pharmaceuticals, Inc.
890.68
-1.75%
 
NTLA Intellia Therapeutics, Inc.
20.02
-5.43%
 
INO Inovio Pharmaceuticals, Inc.
10.13
-0.34%